Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper
Authors:
Open Access
- 31 December 2025
- journal article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (3) , 867-894
Abstract
Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions. This position paper was developed jointly by the European and North American Societies for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN and NASPGHAN), in consultation with patient representatives. A systematic review was performed for identified topics, and two voting rounds with two group meetings led to agreement on 24 statements. The systematic review (reviewing 4366 manuscripts, of which 123 were included in tables of evidence and 213 in support of 23 statements) found similar biologic pathogenesis, and similar or better effectiveness and safety in children older than 2 years compared to adults. Pharmacokinetics were similar in adolescents but dissimilar in younger children. The review also found sufficiently accurate noninvasive endpoints to reflect post‐induction treatment response. There was no significant added benefit for ileocolonoscopy over sigmoidoscopy in ulcerative colitis. Drugs should be approved in children >12 years and ≥40 kg based on extrapolation from adult and real‐world data. While efficacy may be extrapolated to children <40 kg, pharmacokinetics cannot and thus one open‐label single‐arm study should be performed to establish a dose that matches adult exposure‐response from the adult trial in which adolescents may be enrolled if not exposed to placebo. Full colonoscopies should be minimized in the pediatric dosing trial. Efficacy in patients with infantile IBD cannot be extrapolated from adult data.Keywords
This publication has 209 references indexed in Scilit:
- Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient DataClinical Pharmacology & Therapeutics, 2024
- Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial DesignArthritis & Rheumatology, 2023
- Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisClinical Pharmacology & Therapeutics, 2020
- Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative ColitisThe Journal of Clinical Pharmacology, 2018
- Exposure Matching for Extrapolation of Efficacy in Pediatric Drug DevelopmentThe Journal of Clinical Pharmacology, 2016
- Genome-wide methylation profiling in Crohnʼs disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathwayInflammatory Bowel Diseases, 2012
- Established genetic risk factors do not distinguish early and later onset Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseasesInflammatory Bowel Diseases, 2008
- IL-23 receptor (IL-23R) gene protects against pediatric Crohnʼs diseaseInflammatory Bowel Diseases, 2007
- Development and Validation of a Pediatric Crohn's Disease Activity IndexJournal of Pediatric Gastroenterology and Nutrition, 1991